



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 517 325 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention

of the grant of the patent:

31.10.2001 Bulletin 2001/44

(51) Int Cl.7: G01N 33/94, G01N 33/532

(21) Application number: 92201580.5

(22) Date of filing: 02.06.1992

(54) Drug hapten analogues for immunoassays

Hapten-Analoge zur Verwendung in Immunoassays

Analogues d'haptènes pour utilisation dans des essais immunologiques

(84) Designated Contracting States:

AT BE CH DE ES FR GB GR IT LI LU NL SE

(30) Priority: 07.06.1991 US 712329

16.03.1992 US 851435

(43) Date of publication of application:

09.12.1992 Bulletin 1992/50

(73) Proprietor: Johnson & Johnson Clinical

Diagnostics, Inc.

Rochester New York 14650 (US)

(72) Inventors:

- Danielson, Susan Jean,
c/o EASTMAN KODAK COMPANY
Rochester, New York 14650-2201 (US)

- Oenick, Marsha D.,
c/o EASTMAN KODAK COMPANY
Rochester, New York 14650-2201 (US)

- Ponticello, Ignazio,
c/o EASTMAN KODAK COMPANY
Rochester, New York 14650-2201 (US)

- Hilborn, David Alan,
c/o EASTMAN KODAK COMPANY
Rochester, New York 14650-2201 (US)

- (74) Representative: Mercer, Christopher Paul et al
Carpmaels & Ransford
43, Bloomsbury Square
London WC1A 2RA (GB)

(56) References cited:

EP-A- 0 233 690	EP-A- 0 386 644
DE-A- 3 205 506	US-A- 4 244 939

- JOURNAL OF IMMUNOASSAY vol. 4, no. 3, 1983,
pages 209 - 327 ISHIKAWA ET AL.
'Enzyme-labeling of antibodies and their
fragments for enzyme immunoassay and
immunohistochemical staining'

Remarks:

The file contains technical information submitted
after the application was filed and not included in this
specification

EP 0 517 325 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] This invention relates to clinical chemistry, particularly immunoassays.

5 [0002] Immunoassays, which take advantage of natural immunological reactions, have found wide-spread use as analytical techniques in clinical chemistry. Because of the specificity of the reactions, they are particularly advantageous in quantifying biological analytes that are present in very low concentration in biological fluids. Such analytes (called ligands herein) include, for example, antibodies, therapeutic drugs, narcotics, enzymes, hormones, proteins, and so forth.

10 [0003] In competitive binding immunoassays, a labeled drug hapten analogue is placed in competition with unlabeled drug haptens for reaction with a fixed amount of the appropriate antibody. Unknown concentrations of the drug hapten can be determined from the measured signal of either the bound or unbound (that is, free) labeled drug hapten analogue.

[0004] Conventional labels include radioactive tags, enzymes, chromophores, fluorophores, stable free radicals, and enzyme cofactors, inhibitors and allosteric effectors.

15 [0005] Specific requirements for labeled drug hapten analogues (hereafter sometimes LDH) include: 1) at least 65% of the LDH can be bound by excess immobilized antibody; 2) affinity of the LDH for immobilized antibody is such that competition of a fixed amount of LDH with the drug occurs in a therapeutically relevant concentration range; and 3) stability of the LDH against hydrolysis of its enzyme label under storage conditions. Requirements imposed on the drug hapten analogues include: 1) accessibility of the analogue to the immobilized antibody following conjugation with the enzyme label; 2) specific recognition of the labeled analogue by the antibody to the drug; and 3) sufficient reactivity 20 of the drug analogue with the enzyme label, either directly or following activation of the enzyme or analogue, under conditions that do not adversely affect enzyme activity.

[0006] Glucose oxidase (GOD) and alkaline phosphatase (ALP) enzyme labels coupled to barbiturate or hydantoin analogues disclosed in U.S. Patent 4,752,568, especially phenobarbital and phenytoin analogues, gave adequate enzyme labeled analogues for conducting effective competitive immunoassays in the desired format.

25 [0007] The problem is that hydantoin and barbiturate analogues were unsatisfactory for conducting competitive immunoassays when the enzyme horseradish peroxidase (HRP) was used as the label. The coupling reactions between such derivatives and HRP were both slow and incomplete. Moreover, previous phenytoin-HRP and phenobarbital-HRP labels were bound very weakly so that much higher concentrations of label or antibody binding sites would be required to give a readable signal.

30 [0008] U.S. Patent 4,244,939 discloses compounds useful as tracers in radiimmunoassay of barbiturates in which a radioiodinated group is linked to a pyrimidine ring nitrogen atom of the barbiturate.


[0009] EP patent specification 0233690 describes labelled hydantoin conjugate and its use in analytical elements and immunoassays. The label is linked to the 3-nitrogen position of the hydantoin ring with a linkage derived from an aliphatic monocarboxylic acid having from 2 to 12 carbon atoms.

35 [0010] The present invention provides new drug analogues for barbiturates and hydantoins (a) that react with HRP, and other enzymes such as GOD and ALP, faster and more completely, than prior art analogues, (b) to form covalent bonds with HRP, and (c) produce labelled drug analogues that are more readily recognized and tightly bound by antibodies to such analogues. The drug analogues comprise:

40 (a) an active ester group, wherein said active ester group is succinimidoxycarbonyl;
 (b) a nucleus selected from hydantoin or barbiturate derivatives;
 (c) a linking chain linking the active ester group to the selected nucleus;


45 wherein the linking chain has about 5 to 40 atoms consisting of (1) C₁ to C₁₀ alkylene groups, and optionally (2) phenylene groups, and (3) 5 to 7 membered heterocyclic rings (for example, a 1,4-piperazinylene, 2,5-dimethyl-1,4-piperazinylene; 1,3-imidazolidinylene; and 1,3-hexahydrodiazepinylene group) joined into the linking group through ring nitrogen atoms, said groups and rings being bonded to each other through chemical groups selected from (a) esters, including thioesters,

50



55

where Z is O or S; (b) amides,




(c) hetero atoms selected from -O-, -S-, and -NR-; wherein R represents C_1 to C_6 alkyl (for example, methyl, ethyl, propyl, butyl and so forth); and (d) carbonyl, with the proviso that the linking group is other than a derivative of a saturated or unsaturated aliphatic monocarboxylic acid having from 2 to 12 carbon atoms.

10 [0011] More specifically, the preferred new hydantoin and barbiturate active esters of this invention are those conforming to the structure (I):

15

20




25 wherein

25

A represents a hydantoin nucleus of the structure

30


35



or a barbiturate nucleus of the structure

40

45



50 R^1 each independently represents hydrogen, alkyl of 1 to 10 carbon atoms, unsubstituted or substituted phenyl; R^2 , R^4 , R^5 , and R^6 , each independently represents C_1 to C_{10} alkylene or such alkylene groups interrupted with at least one or more ester groups, amide groups, -O-, -S-, and -NR-;

R^3 represents C_1 to C_3 alkylene;

R^7 is an ethylene group;

Z represents -O-, -S-, and -NR-, wherein R represents hydrogen or C_1 to C_6 alkyl, for example, methyl, propyl and hexyl;

m is 0, 1, or 2;

n is 0, 1, or 2;

m + n is > 0 and

55

the total number of atoms comprised in m , n and R^2 is 5 to 40;

and further provided that (i) at least one of the R^1 groups is substituted or unsubstituted phenyl; (ii) one of R^4 , R^5 , and R^6 can be phenylene; (iii) the bracketed components of structure I can appear therein in any order and (iv) the linking group is other than a derivative of a saturated or unsaturated aliphatic monocarboxylic acid having from 2 to 12 carbon atoms.

[0012] Several other advantages are realized by use of the above drug hapten analogues. First, it was found that the active esters of these analogues having short linking chains between the nucleus and the active ester group were sufficiently reactive with HRP to prepare an acceptable enzyme label for use with only some immobilized antibodies.

10 Derivatives with longer linker groups (R^2 plus the bracketed groups) of 8 to 20 atoms between the active ester group and the nucleus gave labels that could be bound by all immobilized antibodies tested. Linking chains in which each Z is $-NR-$ which with the adjacent carbonyl forms an amide group, are particularly useful in analogues of this invention because such chains are more resistant to hydrolysis than chains wherein Z is $-O-$ or $-S-$ so that with the adjacent carbonyl it forms an ester group.

15 [0013] Methods of making the drug hapten analogues of this invention are presented below.

Hydantoin Drug Analogues

20 [0014] The hydantoin drug analogues can be made according to the following preparations in which phenytoin analogues, a species of hydantoin compounds, are made.

Example 1 - Preparation of HD 1, 5,5-Diphenyl-3-[4-[2-(3-succinimidoxycarbonylpropionyloxy)ethylaminocarbonyl]butyl]-hydantoin.

25 Step 1: preparation of 5,5-Diphenyl-3-[4-(2-hydroxyethylaminocarbonyl)butyl]hydantoin.

Part A: First the Acid Chloride is prepared.

30 [0015] A mixture of 3-(4-carboxybutyl)-5,5-diphenyl-2,4-imidazolidinedione (3.52 g, 0.01 mole) thionyl chloride (20 mL), N,N-dimethylformamide (2 drops) and chloroform (50 mL) was stirred at room temperature for 3 hours. The solvent was removed on a rotary evaporator in vacuo, and this product was used directly in the next Part B.

Part B: The Acid Chloride is reacted with Ethanolamine.

35 [0016] The acid chloride in chloroform (50 mL) was added dropwise over 15 minutes to a mixture of ethanolamine (1.2 g, 0.02 mole) and triethylamine (2.4 g, 0.024 mole) in chloroform (100 mL). The mixture was then heated to 60°C for 2 hours and stirred to room temperature for 1 hour. The solution was then washed with 5% hydrochloric acid (2 x 100 mL), washed with saturated sodium bicarbonate solution (100 mL), dried over anhydrous magnesium sulfate, filtered, and the solvent removed on a rotary evaporator. The filtrate was then chromatographed using an aluminum oxide column to give material (3.0 g) showing one spot on TLC. This material was used directly in the next preparation.

40 Step 2: preparation of 3-[4-[2-(3-Carboxypropionyloxy)ethylaminocarbonyl]butyl]-5,5-diphenylhydantoin.

45 [0017] The hydroxy compound of Step 1 (3.0 g, 0.0075 mole), succinic anhydride (1.0 g, 0.01 mole), and dimethylaminopyridine (0.9 g, 0.0075 mole) in chloroform (100 mL) were heated at 50-60°C for 4 hours and allowed to cool to room temperature over the weekend.

[0018] Dichloromethane (300 mL) was added, and the mixture was washed with 5% hydrochloric acid solution (3 x 100 mL), washed with saturated sodium chloride solution (100 mL), dried over anhydrous magnesium sulfate, filtered, and the solvent removed to give a material that gave one spot on TLC.

50


55

Step 3: preparation of HD 1: 5,5-Diphenyl-3-{4-[2-(3-succinimidoxycarbonylpropionyloxy)ethylaminocarbonyl]butyl}hydantoin.

[0019]

5

10



15

20

25

30

[0020] A mixture of the acid from Step 2 (3.0 g, 0.006 mole), N,N'-dicyclohexylcarbodiimide (1.5 g, 0.007 mole), and N-hydroxysuccinimide (0.7 g, 0.006 mole) in chloroform (80 mL) was stirred at room temperature for 20 hours. The mixture was filtered, and the filtrate was concentrated on a rotary evaporator in vacuo. The residue was then chromatographed using silica to give 1.3 g (40% yield). Anal. calc. for $C_{30}H_{32}N_4O_9$: C, 60.8; H, 5.44; N, 9.45. Found: C 59.6; H, 5.51, N, 8.91

35

Example 2 - Preparation of HD 2: 5,5-Diphenyl-3-{4-[4-(3-succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl}-2,4-imidazolidinedione

40

Step 1: preparation of 5,5-Diphenyl-3-(1-piperazinylcarbonylbutyl)hydantoin.

Part A: First, 3-[4-(4-Benzylcarbonylpiperazinylcarbonyl)butyl]-5,5-diphenyl-2,4-imidazolidinedione was prepared.

45

[0021] The acid chloride prepared as described in the preparation of HD 1, *supra*; Part A (.01 mole) was added dropwise over 15 minutes to a mixture of benzyl 1-piperazinecarboxylate (2.4 g, 0.011 mole) and triethylamine (2.0 g, 0.02 mole) in chloroform (50 mL). This mixture was stirred at room temperature overnight, and dichloromethane (300 mL) was added. The mixture was washed with 5% hydrochloric acid (2 x 100 mL), washed with dilute sodium carbonate solution (100 mL), washed with saturated sodium chloride solution (100 mL), dried over anhydrous magnesium sulfate solution, filtered, and the solvent removed on a rotary evaporator in vacuo. The filtrate was then chromatographed to give an oil, 4.3 g (78% yield) which was used directly in the next step.

50

[0022] Part B: The protected amine of Part A (4.8 g, 0.008 mole) and 30-35% hydrogen bromide acetic acid solution (25 mL) was allowed to stir at room temperature for 1.5 hours. This mixture was then poured into diethyl ether (1 L), and the oil which separated was triturated with fresh portions of ether (3 x 1 L). The oil was dissolved in 10% aqueous sodium hydroxide solution (pH=14) and the aqueous solution extracted with dichloromethane (4 x 100 mL). The combined organic solution was washed with saturated sodium chloride solution (150 mL), dried over anhydrous magnesium sulfate, filtered, and the solvent removed in a rotary evaporator in vacuo. The filtrate solidifies to give a white solid (2.6 g, 77% yield). This material was used directly in the next step.


Step 2: preparation of 3-[4-[4-(3-Carboxypropionyl)-1-piperazinylcarbonyl]butyl]-5,5-diphenyl-2,4-imidazolidinedione.

[0023] A mixture of the amine from step 1 above (2.1 g, 0.005 mole) and succinic anhydride (0.54 g, 0.0054 mole) in chloroform (15 mL) was heated for 30 minutes at 50-60°C and allowed to stand at ambient temperature for 20 hours. 5 Dichloromethane (150 mL) was added, and the mixture was washed with 5% hydrochloric acid (2 x 100 mL), saturated sodium chloride solution (100 mL), dried over anhydrous magnesium sulfate, filtered, and the solvent removed on a rotary evaporator in vacuo to give a white solid, 2.5 g (95%) which was used directly in the next step.

10 Step 3: preparation of HD 2: 5,5-Diphenyl-3-[4-[4-(3-succinimidoxy carbonylpropionyl)-1-piperazinylcarbonyl]butyl]-2,4-imidazolidinedione.

[0024]

15



20

25

30

35

45

50

[0025] A mixture of the acid from step 2 (1.56 g, 0.003 mole), N,N'-dicyclohexylcarbodiimide (0.64 g, 0.003 mole), and N-hydroxysuccinimide (0.36 g, 0.003 mole) in chloroform (40 mL) was stirred at room temperature over the weekend. 40 The mixture was filtered and the solvent removed from the filtrate on a rotary evaporator in vacuo to give 1.9 g (100% yield). The solid was chromatographed, and the product fraction was dissolved in dichloromethane (200 mL), washed with dilute sodium carbonate solution (2 x 100 mL), dried over anhydrous magnesium sulfate, filtered, and the solvent removed on a rotary evaporator to give a white solid which gives one spot on TLC. Anal. calc. for C₃₂H₃₅N₅O₈: C, 62.23; H, 5.71; N, 11.34. Found: C, 59.07; H, 5.40; N, 10.45.

Example 3 - Preparation of HD 3, 5,5-Diphenyl-3-[4-[6-(3-succinimidoxy carbonylpropionamido)hexylaminocarbonyl]butyl]-2,4-imidazolidinedione.

Step 1: preparation of 3-[4-(6-Aminohexylaminocarbonyl)butyl]-5,5-diphenyl-2,4-imidazolidinedione.

[0026] Part A: preparation of 3-[4-(6-Benzylloxycarbonylamino hexylaminocarbonyl)butyl]-5,5-diphenyl-2,4-imidazolidinedione.

[0027] The acid chloride prepared as an intermediate in the preparation of HD 1 was treated with N-benzylloxycarbonyl-1,6-hexanediamine by the procedures described in step 1 in the preparation of HD 2, to give 7.5 g, 85% yield, of the protected amine.

[0028] Part B: The protected amine of Part A was treated with hydrobromic acid-acetic acid by the procedures of Step 1, Part B in the preparation of HD 2, to give the free amine which was used in step 3 without purification.

Step 3: preparation of 3-[4-[6-(3-Carboxypropionamido)hexylaminocarbonyl]butyl]-5,5-diphenyl-2,4-imidazolidinedione.

5 [0029] This compound was prepared using the same procedures as step 2 of the HD 2 preparation. Anal. Calc. for C₃₀H₃₈N₄O₆: C, 65.44; H, 6.96; N, 10.17. Found: C, 63.26, H, 7.01; N, 9.39.

Step 4: preparation of HD 3: 5,5-Diphenyl-3-[4-[6-(3-succinimidoxycarbonylpropionamido)hexylaminocarbonyl]butyl]-2,4-imidazolidinedione.

10 [0030]

15


20

25

30

35

40



45 [0031] This material was prepared using the procedures of step 3 in the preparation of HD 2 to give 2.6 g (80% yield), mpt 133-134°C. Anal. Calc. for C₃₄H₄₁N₅O₈: C, 63.05; H, 6.38; N, 10.81. Found: C, 62.91; H, 6.41; N, 10.69.

Barbiturate Drug Analogues

50 [0032] The following preparatory examples 4 to 8 illustrate the preparation of the barbiturate drug hapten analogues for phenobarbital. The analogues are generally prepared by (1) condensing a barbiturate derivative such, as phenobarbital, with an omega-haloalkanecarboxylate ester, (2) saponifying the ester to the corresponding acid, (3) conversion of acid to the corresponding acid chloride, (4) condensation of the acid chloride with N-hydroxysuccinimide, or to further lengthen the linking chain, with a diamine, diol, or aminoalcohol having one of the amine or hydroxy groups blocked and (5) deblocking, condensation with a dicarboxylic acid such as succinic acid, and then condensation with the N-hydroxysuccinimide to produce the analogue.

55 [0033] If desired, the condensation with a half-blocked diamine, diol, or aminoalcohol, and then another diacid can be repeated once or twice more to further lengthen the linking chain. However, the same can be accomplished with fewer steps by using longer chained diacids, diols, diamines, amino alcohols, or haloalkanecarboxylate esters.

Example 4 - Preparation of PB 1: 5-Ethyl-5-phenyl-1-[4-[4-(3-Succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl]-2,4,6(1H,3H,5H)pyrimidinetrione

Step 1: Preparation of 5-Ethyl-6-hydroxy-3-(4-methoxycarbonylbutyl)-5-phenyl-2,4(3H,5H)-pyrimidinedione

[0034] A mixture of phenobarbital (46.5 g, 0.2 mole) and tetrabutylammonium hydroxide (500 mL, 0.2 mole of 0.4M in water) in dichloromethane (500mL) was prepared and to it was added methyl 5-bromovalerate (39.0 g, 0.2 mole). The reaction mixture was stirred vigorously overnight (20 hrs). To this mixture was added saturated sodium chloride solution (100 mL), the organic layer was separated, and the aqueous solution was washed with dichloromethane (2 x 100 mL). The combined organic solution was washed with saturated sodium chloride solution (100mL), dried over anhydrous MgSO_4 , filtered, and the solvent removed.

Step 2: Preparation of 3-(4-Carboxybutyl)-5-ethyl-6-hydroxy-5-phenyl-2,4(3H,5H)-pyrimidinedione

[0035] The 5-ethyl-6-hydroxy-3-(4-methoxycarbonylbutyl)-5-phenyl-2,4(3H,5H)-pyrimidinedione ester (54.0 g, 0.156 mole) of step 1 in dioxane (500 mL), concentrated hydrochloric acid (55 mL), and water (55 mL) was heated at reflux for 4 hrs and at room temperature overnight. The dioxane was removed under reduced pressure, and saturated sodium chloride solution (250 mL) and dichloromethane (400 mL) were added to the residue. The organic layer was separated, and the aqueous solution was extracted with dichloromethane (3 x 150 mL). The combined organic solutions were washed with saturated sodium chloride solution (200 mL), dried over anhydrous MgSO_4 , filtered, and the solvent removed. To the residue was added diethyl ether, and the mixture was placed in a freezer at -16 °C over the weekend, and then filtered.

Step 3: Preparation of 1-(4-chlorocarbonylbutyl)-5-ethyl-5-phenyl-2,4,6(1H,3H,5H)pyrimidinetrione

[0036] A mixture of the acid (6.6 g, 0.2 mole) from preparation 2, thionyl chloride (50 mL), N,N-dimethylformamide (2 drops), and chloroform (80 mL) was stirred at room temperature for 1.5 hrs. The solvent was removed on a rotary evaporator in vacuo, and this product was used directly in the next step 4.

Step 4: Preparation of 1-[4-(4-Benzylloxycarbonyl-1-piperazinylcarbonyl)butyl]-5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione

[0037] The acid chloride of step 3 (0.2 mole) in chloroform (75 mL) was added dropwise over 15 minutes to a mixture of benzyl 1-piperazinecarboxylate (6.0 g, 0.030 mole) and triethylamine (4.0 g, 0.04 mole) in chloroform (100 mL). This mixture was stirred at room temperature for 20 hrs, and dichloromethane was then added (300 mL). The mixture was washed with 10% hydrochloric acid solution (3 x 100 mL), washed with saturated sodium chloride solution (100 mL), dried over anhydrous magnesium sulfate, filtered, and the solvent removed. The residue was then chromatographed on SiO_2 to give a solid.

Step 5: Preparation of 5-Ethyl-5-phenyl-1-[4-(1-piperazinylcarbonyl)butyl]-2,4,6(1H,3H,5H)pyrimidinetrione Hydrobromide

[0038] The protected amine from preparation 4 (6.5 g, 0.012 mole) and 30-35% hydrogen bromide-acetic acid solution (30 mL) was allowed to stir at room temperature for 1.5 hrs. The mixture was then poured into ethyl acetate (2 L), stirred for 1 hr, filtered, and the solid washed with 500 mL ethyl acetate.

Step 6: Preparation of 1-[4-[4-(3-Carboxypropionyl)-1-piperazinylcarbonyl]butyl]-5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione


[0039] The amine of step 5 (4.8 g, 0.01 mole), succinic anhydride (1.2 g, 0.012 mole), and triethylamine (2.2 g, 0.02 mole) in chloroform (150 mL) were heated for 30 min at 50-60 °C (hot water) and allowed to stir at ambient temperature for 16 hrs. Dichloromethane (200 mL) was added, the mixture was washed with 10% hydrochloric acid solution (3 x 100 mL), saturated sodium chloride solution (100 mL), dried over anhydrous magnesium sulfate, filtered, and the solvent removed on a rotary evaporator in vacuo to give a white solid, 3.3 g (66%). This material was chromatographed using a SiO_2 column to give a white solid.

Step 7: Preparation of 5-Ethyl-5-phenyl-1-[4-[4-(3-Succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl]-2,4,6(1H,3H,5H)pyrimidinetrione

[0040]

5

10



15

20

30

35

40

45

50

55

[0041] A mixture of the acid from step 6 (3.4 g, 0.007 mole), N,N'-dicyclohexylcarbodiimide (1.6 g, 0.008 mole), and N-hydroxysuccinimide (1.0 g, 0.008 mole) in chloroform (75 mL) was stirred at room temperature for 20 hrs. The mixture was filtered, and ethyl acetate (100 mL) was added. The organic solution was washed with water (2 x 100 mL), saturated sodium chloride solution (50 mL), dried over anhydrous magnesium sulfate, filtered, and the solvent removed on a rotary evaporator under vacuo. A portion of the solid was chromatographed to give a white solid.

Example 5 - Preparation of PB 3, 5-Ethyl-5-phenyl-1-[4-[2-(3-succinimidoxycarbonylpropionyloxy)ethylaminocarbonyl]butyl]-2,4,6(1H,3H,5H)-pyrimidinetrione

Step 1: Preparation of 5-Ethyl-1-[4-(2-hydroxyethylaminocarbonyl)butyl]-5-phenyl-2,4,6(1H,3H,5H)pyrimidinetrione

[0042] This material was prepared as outlined in step 4 of preparatory example 4 except using 2-hydroxyethylamine in place of the benzyl 1-piperazinecarboxylate.


Step 2: Preparation of 1-[4-[2-(3-Carboxypropionyloxy)ethylaminocarbonyl] butyl]-5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione

[0043] A mixture of the product from step 1 (2.9 g, 0.007 mole), succinic anhydride (0.7 g, 0.007 mole), and dimethylaminopyridine (0.9 g, 0.007 mole) in chloroform (100 mL) was heated with hot water (50-60 °C) for 30 min and then stirred at room temperature for 3 days. Dichloromethane (300 mL) was added, and the mixture was washed with 10% hydrochloric acid solution (2 x 100 mL), washed with saturated sodium chloride solution (100 mL), dried over anhydrous magnesium sulfate, filtered, and solvent removed to give an oil which was used directly in the next step.

Step 3: Preparation of PB 3, 5-Ethyl-5-phenyl-1-[4-[2-(3-succinimidoxycarbonylpropionyloxy)ethylaminocarbonyl]butyl]-2,4,6(1H,3H,5H)-pyrimidinetrione

[0044]

5



15

[0045] This material was prepared using the procedure outlined in step 7 of preparatory example 4 starting with the acid of step 2 of this example.

20 Example 6 - Preparation of PB 4, 5-Ethyl-5-phenyl-1-[4-[3-(3-succinimidoxycarbonylpropionamido)propylaminocarbonyl]butyl]-2,4,6(1H,3H,5H)-pyrimidinetrione

Step 1: Preparation of 1-[4-(3-Benzylloxycarbonylaminopropylaminocarbonyl)butyl]-5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione

25 [0046] This material was prepared using the procedure outlined in step 4, preparatory example 4, except substituting N-benzylloxycarbonyl-1,3-propanediamine for the benzyl 1-piperazinecarboxylate, and the crude material was used in the next step.

30 Step 2: Preparation of 1-[4-(3-Aminopropylaminocarbonyl)butyl]-5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
Hydrobromide

[0047] This material was prepared as in step 5, preparatory example 4 (except starting with the amide of step 1 of this example to give an oil when poured into ethyl ether.

35 Step 3: Preparation of 1-[4-(3-Carboxypropionamido)propylaminocarbonyl]butyl]-5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione


[0048] This material was prepared by the procedure of step 6, preparatory example 4, except starting with the amine from step 2 of this example to give the acid.

40

Step 4: Preparation of PB 4, 5-ethyl-5-phenyl-1-[4-[3-(3-succinimidoxycarbonylpropionamido)propylaminocarbonyl]butyl]-2,4,6(1H,3H,5H)-pyrimidinetrione

[0049]

45




55 [0050] This material was prepared using the procedure of step 7, preparatory example 4 except starting with the acid of step 3 of this example.

Example 7 - Preparation of PB 5, 5-Ethyl-5-phenyl-1-{4-[6-(3-succinimidoxycarbonylpropionamido)-hexylaminocarbonyl]butyl}-2,4,6(1H,3H,5H)-pyrimidinetrione

[0051]

5

10



15

[0052] This compound was prepared by the sequence of reactions of preparation example 6 except substituting N-benzyloxycarbonyl-1,6-hexanediamine for the benzyloxycarbonyl-1,3-propanediamine in step 1, and the respective reaction products thereafter in steps 2, 3, and 4 of preparation example 6.

20

[0053] We have prepared new labeled drug hapten analogues from the drug hapten analogues of this invention that are useful in competitive immunoassays for drugs that possess the hydantoin or barbiturate nucleus, particularly phenytoin and phenobarbital. The labels are those commonly used in immunoassays with labels having an amine or sulfhydryl group such as enzymes.

Claims


25

1. Drug analogues comprising:

- (A) an active ester group, wherein said active ester group is succinimidoxycarbonyl;
- (B) a nucleus selected from hydantoin or barbiturate; and
- (C) a linking chain linking the 3-position of the nucleus to the active ester group; wherein the linking chain has about 5 to 40 atoms consisting of
 - (1) at least one C₁ to C₁₀ alkylene group, and optionally
 - (2) one or more phenylene groups, and/or
 - (3) one or more 5 to 7 membered heterocyclic rings joined into the linking group through ring nitrogen atoms, said groups and rings being bonded to each other through chemical groups selected from

(a) esters


40



45

where Z is O or S;
(b) amides,

50




55

(c) hetero atoms selected from -O-, -S-, and -NR-; wherein R represents C₁ to C₆ alkyl; and
(d) carbonyl,
with the proviso that the linking group is other than a derivative of a saturated or unsaturated aliphatic monocarboxylic acid having from 2 to 12 carbon atoms.

2. The drug analogue of claim 1
wherein the linking chain includes a heterocyclic ring selected from 1,4-piperazinylene, 2,5-dimethyl-1,4-piperazinylene, 1,3-imidazolidinylene, and 1,3-hexahydrodiazepinylene.

5 3. The drug analogue of claim 1 conforming to the structure:


10



15

wherein


20 A represents a hydantoin nucleus of the structure



25

30

or a barbiturate nucleus of the structure



35

40

45 R¹ each independently represents hydrogen, alkyl of 1 to 10 carbon atoms, unsubstituted or substituted phenyl; R², R⁴, R⁵, and R⁶, each independently represents C₁ to C₁₀ alkylene or such alkylene groups interrupted with at least one or more ester groups, amide groups, -O-, -S-, and -NR-;

R³ represents C₁ to C₃ alkylene;

R⁷ is an ethylene;

Z represents -O-, -S-, and -NR-, wherein R represents hydrogen or C₁ to C₆ alkyl;
m is 0, 1, or 2;

n is 0, 1, or 2;

m + n is > 0 and

the total number of atoms comprised in m, n and R² is 5 to 40;

55 and further provided that (i) at least one of the R¹ groups is substituted or unsubstituted phenyl;

(ii) one of R⁴, R⁵, and R⁶ can be phenylene;

(iii) the bracketed components of structure I can appear therein in any order and (iv) the linking group is other than a derivative of a saturated or unsaturated monocarboxylic acid having from 2 to 12 carbon atoms.

4. The drug analogue derivatives of claim 3 according to structure I wherein

each R¹ independently represents phenyl or ethyl;
 R² is butylene;
 R³, R⁴, R⁵ and R⁶, each independently, represent ethylene or hexylene;
 Z represents -O- or -NH; and
 R⁷ represents ethylene.

5

5. The drug analogue according to claim 1, selected from

10

- 5,5-Diphenyl-3-[4-[4-(3-succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl]-2,4-imidazolidinedione;
- 5,5-Diphenyl-3-(4-[2-(3-succinimidoxycarbonylpropionyloxy)ethylaminocarbonyl]butyl)-2,4-imidazolidinedione
- 5,5-Diphenyl-3-[4-[6-(3-succinimidoxycarbonylpropionamido)hexylaminocarbonyl]butyl]-2,4-imidazolidinedione.

15

5-Ethyl-5-phenyl-1-[4-[6-(3-succinimidoxycarbonylpropionamido)hexylaminocarbonyl]butyl]-2,4,6(1H,3H,5H)-pyrimidinetrione

5-Ethyl-5-phenyl-1-[4-[3-(3-succinimidoxycarbonylpropionamido)propylaminocarbonyl]butyl]-2,4,6(1H,3H,5H)-pyrimidinetrione

20

5-Ethyl-5-phenyl-1-[4-[2-(3-succinimidoxycarbonylpropionyloxy)ethylaminocarbonyl]butyl]-2,4,6(1H,3H,5H)-pyrimidinetrione and

5-Ethyl-5-phenyl-1-[4-[4-(3-Succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl]-2,4,6(1H,3H,5H)-pyrimidinetrione

25

Patentansprüche

1. Wirkstoff-Analoga, umfassend:

(A) Eine aktive Estergruppe, wobei die aktive Estergruppe ein Succinimidoxycarbonyl ist;

(B) Einen Kern, ausgewählt aus Hydantoin oder Barbiturat; und

(C) eine verbindende Kette, welche die 3-Position des Kerns mit der aktiven Estergruppe verbindet;

35

wobei die verbindende Kette ungefähr 5 bis 40 Atome aufweist, bestehend aus

(1) mindestens einer (C₁ bis C₁₀)-Alkylengruppe, und gegebenenfalls


40

(2) einer oder mehreren Phenylengruppen, und/oder

(3) einem oder mehreren 5- bis 7-gliedrigen heterozyklischen Ringen, die in die verbindende Gruppe über Ring-Stickstoff-Atome eingebunden sind, wobei die Gruppen und Ringe miteinander über chemische Gruppen verbunden sind, die ausgewählt sind aus

45


(a) Estern



55

worin Z O oder S ist;

(b) Amilden,



5

(c) Hetero-Atomen, ausgewählt aus -O-, -S- und -NR-; worin R (C₁ bis C₆)-Alkyl bedeutet; und

10

(d) Carbonyl,

15


unter der Voraussetzung, daß die verbindende Gruppe kein Derivat einer gesättigten oder ungesättigten aliphatischen Monocarboxylsäure mit 2 bis 12 Kohlenstoffatomen ist.

20

2. Wirkstoff-Analogon nach Anspruch 1, wobei die verbindende Gruppe einen heterozyklischen Ring einschließt, ausgewählt aus 1,4-Piperazinylen, 2,5-Dimethyl-1,4-piperazinylen, 1,3-Imidazolidinylen und 1,3-Hexahydrodiazepinylen.

3. Wirkstoff-Analogon nach Anspruch 1, entsprechend der Struktur:


25



30

worin A einen Hydantionkern der Struktur


35



40

oder einen Barbituratkern der Struktur

45



50

bedeutet;

R¹ jeweils unabhängig voneinander Wasserstoff, Alkyl aus 1 bis 10 Kohlenstoffatomen, nicht-substituiertes oder substituiertes Phenyl bedeutet;

55

R², R⁴, R⁵ und R⁶ jeweils unabhängig voneinander (C₁ bis C₁₀)-Alkylen bedeuten oder solche Alkylengruppen, die mit mindestens einer oder mehreren Estergruppen, Amidgruppen, -O-, -S- und -NR- unterbrochen sind;

R³ C₁ bis C₃-Alkylen bedeuten;

R₇ ein Ethylen ist;

5 Z-O-, -S- und -NR- bedeuten, worin R Wasserstoff oder C₁ bis C₆-Alkyl bedeuten;

m 0, 1 oder 2 ist;

n 0, 1 oder 2 ist;

10 m + n > 0 ist und

die Gesamtzahl der Atome, die von m, n und R² umfaßt wird, 5 bis 40 ist;

15 und weiter vorausgesetzt, daß (i) mindestens eine der R¹-Gruppen substituiertes oder nicht-substituiertes Phenyl ist;

(ii) einer von R⁴, R⁵ und R⁶ Phenyle sein kann;

20 (iii) die in Klammern gesetzten Komponenten von Struktur I darin in jeder Reihenfolge auftreten können und (iv) die verbindende Gruppe kein Derivat einer gesättigten oder ungesättigten Monocarboxylgruppe mit 2 bis 12 Kohlenstoffatomen ist.

4. Derivate des Wirkstoff-Analogons nach Anspruch 3, gemäß der Struktur I, worin

25 jedes R¹ unabhängig voneinander Phenyl oder Ethyl bedeutet;

R² Butylen ist;

30 R³, R⁴, R⁵ und R⁶ jeweils unabhängig voneinander Ethylen oder Hexylen bedeuten;

Z-O- oder -NH- bedeuten; und

35 R⁷ Ethylen bedeutet.

5. Wirkstoff-Analogon nach Anspruch 1, ausgewählt aus

5,5-Diphenyl-3-[4-[4-(3-succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl]-2,4-imidazolidindion;

40 5,5-Diphenyl-3-[4-[2-(3-succinimidoxycarbonylpropionyloxy)ethylaminocarbonyl]butyl]-2,4-imidazolidindion

5,5-Diphenyl-3-[4-[6-(3-succinimidoxycarbonylpropionamido)hexylaminocarbonyl]butyl]-2,4-imidazolidindion;

45 5-Ethyl-5-phenyl-1-[4-[6-(3-succinimidoxycarbonylpropionamido)hexylaminocarbonyl]butyl]-2,4,6 (1H, 3H, 5H)-pyrimidintron;

5-Ethyl-5-phenyl-1-[4-[3-(3-succinimidoxycarbonylpropionamido)propylaminocarbonyl]butyl]-2,4,6 (1H, 3H, 5H)-pyrimidintron;

50 5-Ethyl-5-phenyl-1-[4-[2-(3-succinimidoxycarbonylpropionyloxy)ethylaminocarbonyl]butyl]-2,4,6 (1H, 3H, 5H)-pyrimidintron; und

55 5-Ethyl-5-phenyl-1-[4-[4-(3-succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl]-2,4,6 (1H, 3H, 5H) pyrimidintron.

Revendications


1. Analogues de médicaments comprenant:

5 (A) un groupe ester actif, dans lequel ledit groupe ester actif est un groupe succinimidoxycarbonyle;
 (B) un noyau choisi parmi l'hydantoïne ou le barbiturate; et
 (C) une chaîne de liaison reliant la position 3 du noyau au groupe ester actif;


10 où la chaîne de liaison possède environ 5 à 40 atomes constitués de

15 (1) au moins un groupe alkylène en C_1 à C_{10} , et éventuellement
 (2) un ou plusieurs groupes phénylène, et/ou
 (3) un ou plusieurs noyaux hétérocycliques à 5 à 7 chaînons reliés au groupe de liaison par les atomes d'azote du noyau, lesdits groupes et noyaux étant liés les uns aux autres par l'intermédiaire de groupes chimiques choisis parmi

20 (a) les esters, notamment les thioesters



30 où Z est O ou S;
 (b) les amides




40 (c) les hétéroatomes choisis parmi -O-, -S-, et -NR-; où R représente un groupe alkyle en C_1 à C_6 ; et
 (d) les groupes carbonyle,

à condition que le groupe de liaison soit autre qu'un dérivé d'un acide monocarboxylique aliphatique saturé ou insaturé comportant de 2 à 12 atomes de carbone.

45 2. Analogue de médicament selon la revendication 1
 dans lequel la chaîne de liaison contient un noyau hétérocyclique choisi parmi les noyaux 1,4-pipérazinylène, 2,5-diméthyl-1,4-pipérazinylène, 1,3-imidazolidinylène et 1,3-hexahydrodiazépinylenne.


50 3. Analogue de médicament selon la revendication 1 répondant à la structure:



dans laquelle

A représente un noyau hydantoïne de structure


5



10

ou un noyau barbiturate de structure

15



20

chaque radical R¹ représente indépendamment un atome d'hydrogène ou un groupe alkyle de 1 à 10 atomes de carbone ou phényle non substitué ou substitué;

chacun des radicaux R², R⁴, R⁵ et R⁶ représente indépendamment un groupe alkylène en C₁ à C₁₀ ou de tels groupes alkylène interrompus par au moins un ou plusieurs groupes ester, groupes amidé, -O-, -S-, et -NR-;

R³ représente un groupe alkylène en C₁ à C₃;

R⁷ est un éthylène;

Z représente -O-, -S-, et -NR-, où R représente un atome d'hydrogène ou un groupe alkyle en C₁ à C₆;

m vaut 0, 1, ou 2;

n vaut 0, 1, ou 2;

m + n est > 0 et

30

le nombre total d'atomes compris dans m, n et R² est de 5 à 40; et à condition également (i) qu'au moins un des groupes R¹ soit un groupe phényle substitué ou non substitué; (ii) qu'un des radicaux R⁴, R⁵ et R⁶ puisse être un groupe phényle; (iii) que les constituants de la structure I entre crochets puisse s'y trouver dans n'importe quel ordre et (iv) que le groupé de liaison soit autre qu'un dérivé d'un acide monocarboxylique aliphatique saturé ou insaturé comportant de 2 à 12 atomes de carbone.

35

4. Dérivés d'analogues de médicament selon la revendication 3 répondant à la structure I dans laquelle

chaque R¹ représente indépendamment un groupe phényle ou éthyle;

R² est un groupe butylène;

40

R³, R⁴, R⁵ et R⁶, chacun indépendamment des autres, représentent des groupes éthylène ou hexylène;

Z représente -O- ou -NH; et

R⁷ représente un groupe éthylène.

45

5. Analogue de médicament selon la revendication 1, choisi parmi

la 5,5-diphényl-3-{4-[4-(3-succinimidoxycarbonylpropionyl)-1-pipérazinylcarbonyl]butyl)-2,4-imidazolidinedione;

la 5,5-diphényl-3-(4-[2-(3-succinimidoxycarbonylpropionyloxy)éthylaminocarbonyl]butyl)-2,4-imidazolidinedione

50

la 5,5-diphényl-3-(4-[6-(3-succinimidoxycarbonylpropionamido)hexylaminocarbonyl]butyl)-2,4-imidazolidinedione.

la 5-éthyl-5-phényl-1-(4-[6-(3-succinimidoxycarbonylpropionamido)hexylaminocarbonyl]butyl)-2,4,6-(1H,3H,5H)pyrimidinetrione

55

la 5-éthyl-5-phényl-1-(4-[3-(3-succinimidoxycarbonylpropionamido)-propylaminocarbonyl]butyl)-2,4,6-(1H,3H,5H)pyrimidinetrione

la 5-éthyl-5-phényl-1-(4-[2-(3-succinimidoxycarbonylpropionyloxy)éthylaminocarbonyl]butyl)-2,4,6-(1H,3H,5H)pyrimidinetrione et

la 5-éthyl-5-phényl-1-(4-[4-(3-succinimidoxycarbonylpropionyl)-1-pipérazinylcarbonyl]butyl)-2,4,6-(1H,3H,

5H)pyrimidinetrione.

5

10

15

20

25

30

35

40

45

50

55